CRISPR Therapeutics AG CRSP NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • CH • USD

SharesGrow Score

48/100

2/7 Pass

SharesGrow Intrinsic Value

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

CRISPR Therapeutics AG (CRSP) generated $-345.01M in operating cash flow for fiscal year 2025. After capital expenditures of $914K, free cash flow was $-345.93M.

Free cash flow margin was -9855.5% of revenue. Cash conversion ratio was 0.59x, suggesting some earnings are non-cash.

Criteria supported by this page:

HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
MOAT (27/100, Fail) — limited free cash flow weakens the competitive position
INCOME (10/100) — Cash conversion ratio was 0.59x suggests some earnings are non-cash items

Overall SharesGrow Score: 48/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score

48/100

SG Score

View full scorecard →

✓

VALUE

88/100

Price-to-Earnings & upside

→ Valuation

FUTURE

52/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

27/100

Proven by this page

GROWTH

58/100

→ Income

✗

INCOME

10/100

→ Income

CRISPR Therapeutics AG Cash Flow History

Metric	TTM	FY2025	FY2024	FY2023	FY2022
Operating Cash Flow	$-345.01M	$-345.01M	$-142.77M	$-260.38M	$-495.74M
Capital Expenditure	$-914K	$-914K	$-1.9M	$-11.97M	$-37.19M
Free Cash Flow	$-345.93M	$-345.93M	$-144.68M	$-272.35M	$-532.93M